These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 31439369

  • 1. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
    van Leenders GJLH, Kweldam CF, Hollemans E, Kümmerlin IP, Nieboer D, Verhoef EI, Remmers S, Incrocci L, Bangma CH, van der Kwast TH, Roobol MJ.
    Eur Urol; 2020 Feb; 77(2):191-198. PubMed ID: 31439369
    [Abstract] [Full Text] [Related]

  • 2. Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.
    Seyrek N, Hollemans E, Andrinopoulou ER, Osanto S, Pelger RCM, van der Poel HG, Bekers E, Remmers S, Schoots IG, van Leenders GJLH.
    Virchows Arch; 2022 Jun; 480(6):1149-1157. PubMed ID: 35157140
    [Abstract] [Full Text] [Related]

  • 3. Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.
    Kweldam CF, Kümmerlin IP, Nieboer D, Steyerberg EW, Bangma CH, Incrocci L, van der Kwast TH, Roobol MJ, van Leenders GJ.
    Mod Pathol; 2017 Aug; 30(8):1126-1132. PubMed ID: 28530220
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
    Roobol MJ, Verbeek JFM, van der Kwast T, Kümmerlin IP, Kweldam CF, van Leenders GJLH.
    Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate: A Survey of Genitourinary Subspecialists.
    Gandhi JS, Smith SC, Paner GP, McKenney JK, Sekhri R, Osunkoya AO, Baras AS, DeMarzo AM, Cheville JC, Jimenez RE, Trpkov K, Colecchia M, Ro JY, Montironi R, Menon S, Hes O, Williamson SR, Hirsch MS, Netto GJ, Fine SW, Sirohi D, Kaushal S, Sangoi A, Robinson BD, Kweldam CF, Humphrey PA, Hansel DE, Schultz L, Magi-Galluzzi C, Przybycin CG, Shah RB, Mehra R, Kunju LP, Aron M, Kryvenko ON, Kench JG, Kuroda N, Tavora F, van der Kwast T, Grignon DJ, Epstein JI, Reuter VE, Amin MB.
    Am J Surg Pathol; 2020 May; 44(5):673-680. PubMed ID: 31876580
    [Abstract] [Full Text] [Related]

  • 8. Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes.
    Shah RB, Nguyen JK, Przybycin CG, Reynolds JP, Cox R, Myles J, Klein E, McKenney JK.
    Histopathology; 2019 Sep; 75(3):346-353. PubMed ID: 31012493
    [Abstract] [Full Text] [Related]

  • 9. Intraductal Adenocarcinoma of the Prostate With Cribriform or Papillary Ductal Morphology: Rare Biopsy Cases Lacking Associated Invasive High-grade Carcinoma.
    Russell DH, Epstein JI.
    Am J Surg Pathol; 2022 Feb 01; 46(2):233-240. PubMed ID: 34619708
    [Abstract] [Full Text] [Related]

  • 10. Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies.
    Rijstenberg LL, Hansum T, Kweldam CF, Kümmerlin IP, Remmers S, Roobol MJ, van Leenders GJLH.
    Histopathology; 2022 Jun 01; 80(7):1041-1049. PubMed ID: 35384019
    [Abstract] [Full Text] [Related]

  • 11. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
    Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Ishida R, Sano T, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T.
    Prostate; 2019 Jul 01; 79(10):1065-1070. PubMed ID: 31025722
    [Abstract] [Full Text] [Related]

  • 12. Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN Tools.
    Downes MR, Liu KN, Yu Y, Lajkosz K, Kroon LJ, Hollemans E, Fleshner N, Finelli A, van Leenders GJLH, Iczkowski KA, van der Kwast TH.
    Clin Genitourin Cancer; 2024 Feb 01; 22(1):47-55. PubMed ID: 37558528
    [Abstract] [Full Text] [Related]

  • 13. PIN-like (Ductal) Adenocarcinoma of the Prostate.
    Paulk A, Giannico G, Epstein JI.
    Am J Surg Pathol; 2018 Dec 01; 42(12):1693-1700. PubMed ID: 30138215
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer.
    Zhu S, Zhao JG, Chen JR, Liu ZH, Sun GX, Wang ZP, Ni YC, Dai JD, Shen PF, Zeng H.
    Asian J Androl; 2020 Dec 01; 22(5):519-525. PubMed ID: 31710002
    [Abstract] [Full Text] [Related]

  • 16. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores.
    Okubo Y, Sato S, Hasegawa C, Koizumi M, Suzuki T, Yamamoto Y, Yoshioka E, Ono K, Washimi K, Yokose T, Kishida T, Miyagi Y.
    Hum Pathol; 2023 May 01; 135():99-107. PubMed ID: 36738975
    [Abstract] [Full Text] [Related]

  • 17. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
    Jeyapala R, Savio AJ, Olkhov-Mitsel E, Kamdar S, Zhao F, Cuizon C, Liu RSC, Zlotta A, Fleshner N, van der Kwast T, Bapat B.
    Eur Urol Oncol; 2019 May 01; 2(3):231-238. PubMed ID: 31200836
    [Abstract] [Full Text] [Related]

  • 18. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.
    Seyrek N, Hollemans E, Osanto S, Pelger RCM, van der Poel HG, Bekers E, Bangma CH, Rietbergen J, Roobol MJ, Schoots IG, van Leenders GJLH.
    Histopathology; 2022 Feb 01; 80(3):558-565. PubMed ID: 34706119
    [Abstract] [Full Text] [Related]

  • 19. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.
    Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, Ghabili K, Agostino J, Macura KJ, Carter HB, Schaeffer EM, Partin AW, Sokoll LJ, Ross AE.
    Prostate Cancer Prostatic Dis; 2017 Jun 01; 20(2):228-233. PubMed ID: 28117387
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.
    Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Roobol MJ, Helleman J, van Leenders GJLH.
    Histopathology; 2020 Apr 01; 76(5):755-762. PubMed ID: 31944367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.